Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > sold some kept some
View:
Post by klank37 on Sep 24, 2010 12:14pm

sold some kept some

I did my usual call to the company and it appear to me that it isn't anytime soon (1 year) before anything of substance will happen. No enrollment for the new trial is on the way, european not before that time,sure at least China is part of the picture and I'm sure things will pan out but ...not ready to ride the wave of uncertainty will use the money for better more immediate story for now.
Now i know what you're going to say Isaloser247 so save your finger tip.

I like to thing that my post might save some grief to some for the immediate action that seems obvious to me now.
And of course that is only my opinion,but make that phone call yourself

Comment by ngerrits on Sep 24, 2010 3:23pm
I wonder why Goldman Sachs has bought about 1M shares at around .35 the last 3 weeks if its dead money.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities